A Longitudinal Study of Medial Temporal Lobe Volumes in Graves Disease.
Graves disease
amygdala
cognition
depression
hippocampus
longitudinal
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
24 03 2022
24 03 2022
Historique:
received:
09
08
2021
pubmed:
10
11
2021
medline:
16
4
2022
entrez:
9
11
2021
Statut:
ppublish
Résumé
Neuropsychiatric symptoms are common features of Graves disease (GD) in hyperthyroidism and after treatment. The mechanism behind these symptoms is unknown, but reduced hippocampal volumes have been observed in association with increased thyroid hormone levels. This work aimed at investigating GD influence on regional medial temporal lobe (MTL) volumes. Sixty-two women with newly diagnosed GD underwent assessment including magnetic resonance (MR) imaging in hyperthyroidism and 48 of them were followed up after a mean of 16.4 ± 4.2 SD months of treatment. Matched thyroid-healthy controls were also assessed twice at a 15-month interval. MR images were automatically segmented using multiatlas propagation with enhanced registration. Regional medial temporal lobe (MTL) volumes for amygdalae and hippocampi were compared with clinical data and data from symptom questionnaires and neuropsychological tests. Patients had smaller MTL regions than controls at inclusion. At follow-up, all 4 MTL regions had increased volumes and only the volume of the left amygdala remained reduced compared to controls. There were significant correlations between the level of thyrotropin receptor antibodies (TRAb) and MTL volumes at inclusion and also between the longitudinal difference in the levels of free 3,5,3'-triiodothyronine and TRAb and the difference in MTL volumes. There were no significant correlations between symptoms or test scores and any of the 4 MTL volumes. Dynamic alterations in the amygdalae and hippocampi in GD reflect a previously unknown level of brain involvement both in the hyperthyroid state of the condition and after treatment. The clinical significance, as well as the mechanisms behind these novel findings, warrant further study of the neurological consequences of GD.
Identifiants
pubmed: 34752624
pii: 6424408
doi: 10.1210/clinem/dgab808
pmc: PMC8947220
doi:
Substances chimiques
Immunoglobulins, Thyroid-Stimulating
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040-1052Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Références
J Clin Endocrinol Metab. 2002 May;87(5):1949-54
pubmed: 11994323
Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E54-61
pubmed: 11404222
Thyroid. 2019 Mar;29(3):322-331
pubmed: 30667296
Eur Thyroid J. 2015 Sep;4(Suppl 1):113-8
pubmed: 26601082
Public Health Nutr. 2007 Dec;10(12A):1554-70
pubmed: 18053280
Neuroimage. 2010 May 15;51(1):221-7
pubmed: 20114079
J Intern Med. 1996 Feb;239(2):165-71
pubmed: 8568485
J Neurol Neurosurg Psychiatry. 2016 May;87(5):493-500
pubmed: 25986365
Arch Gen Psychiatry. 2012 Nov;69(11):1169-78
pubmed: 23117638
Neurosci Biobehav Rev. 2006;30(7):1004-31
pubmed: 16730374
Assessment. 2003 Jun;10(2):151-9
pubmed: 12801187
Front Endocrinol (Lausanne). 2014 Mar 31;5:40
pubmed: 24744751
Eur J Endocrinol. 2006 Apr;154(4):501-10
pubmed: 16556711
Biol Psychiatry. 2018 Feb 1;83(3):244-253
pubmed: 29217296
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Eur J Endocrinol. 2010 Jan;162(1):161-7
pubmed: 19797502
Am J Psychiatry. 2000 Jan;157(1):115-8
pubmed: 10618023
Qual Life Res. 2015 Mar;24(3):769-80
pubmed: 25194574
Thyroid. 2005 Nov;15(11):1279-86
pubmed: 16356093
Brain Inj. 2010 Jan;24(1):2-12
pubmed: 20001478
Thyroid. 2014 Mar;24(3):433-40
pubmed: 24205791
Curr Opin Endocrinol Diabetes Obes. 2018 Aug;25(4):285-289
pubmed: 29746308
Brain Inj. 2009 Dec;23(13-14):1027-40
pubmed: 19909051
J Clin Endocrinol Metab. 1996 Aug;81(8):2986-93
pubmed: 8768863
Biomed Res Int. 2017;2017:2061935
pubmed: 28607927
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):359-70
pubmed: 22632371
BMJ Open. 2019 Nov 3;9(11):e031168
pubmed: 31685507
Biol Psychiatry. 2007 Oct 15;62(8):847-55
pubmed: 17544382
Eur J Endocrinol. 2004 Nov;151(5):549-55
pubmed: 15538931
Acta Endocrinol (Copenh). 1986 Jun;112(2):185-91
pubmed: 3739553
BMC Med Imaging. 2015 Feb 18;15:5
pubmed: 25879816
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Eur Thyroid J. 2014 Sep;3(3):173-8
pubmed: 25538899
Eur J Radiol. 2014 Jan;83(1):e43-8
pubmed: 24161779
Psychol Med. 2015 Apr;45(6):1219-28
pubmed: 25273347
Acta Psychiatr Scand. 1994 Jan;89(1):21-8
pubmed: 8140903
Curr Alzheimer Res. 2014 Mar;11(3):239-52
pubmed: 24484275
Mov Disord. 2015 Feb;30(2):245-52
pubmed: 25600157
J Neurol Sci. 2011 Mar 15;302(1-2):114-7
pubmed: 21196016
Hum Brain Mapp. 2010 Sep;31(9):1339-47
pubmed: 20839293
J Neural Transm (Vienna). 2018 Feb;125(2):229-238
pubmed: 29159580
PLoS One. 2015 Jul 10;10(7):e0129211
pubmed: 26161961
PLoS One. 2017 Aug 28;12(8):e0180866
pubmed: 28846692
J Clin Endocrinol Metab. 1988 Oct;67(4):853-6
pubmed: 3417852